Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

@inproceedings{Xie2009CostutilityAO,
  title={Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis},
  author={Feng Xie and Gordon Blackhouse and Nazila Assasi and Kathryn Gaebel and Diana Robertson and Ron Goeree},
  booktitle={Cost effectiveness and resource allocation : C/E},
  year={2009}
}
OBJECTIVE To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon from the perspective of a publicly… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

l'assurance maladie du Quebec: List of Medications 2008 [http://www.ramq.gouv.qc.ca/en/regie/lois/liste_med.shtml

Regie de
Quebec: Gouvernement du Quebec Accessed 2009 Jan • 2009
View 1 Excerpt

Investigational therapies in the medical management of Crohn ' s disease

Korzenik
Humira ® ( adalimumabAbbott Laboratories Ltd • 2008

Adalimumab for refractory Crohn's disease and ulcerative colitis [ACP Brief - Spring 2007 prioritization, FINAL] Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH)

SL Ndegwa
2007
View 1 Excerpt

Investigational therapies in the medical management of Crohn's disease. UpToDate [database online

JR Korzenik
Waltham (MA): UpToDate • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…